0840 GMT - Alibaba Health Information Technology's long-term growth remains intact despite near-term moderation in profit growth, say UOB Kay Hian's Sunny Chen and Carol Dou in a note. The analysts see structural growth opportunities for the healthcare subsidiary of Alibaba Group, buoyed by sustained innovative-drug momentum, expanding artificial-intelligence adoption, and deeper synergy with the Alibaba ecosystem. They project the company's FY 2026-2028 revenue and adjusted net profit to grow at compound annual growth rates of 12% and 15%, respectively. Still, UOB KH cuts its target price to HK$5.20 from HK$6.00 to reflect faster investment in innovative drugs and AI. The brokerage retains its buy rating. Shares closed 2.0% lower at HK$3.91. (megan.cheah@wsj.com)
(END) Dow Jones Newswires
May 20, 2026 04:40 ET (08:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments